Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 3 5 M IN PLASTIC CONTAINER versus AMINOSYN II 4 25 W ELECTROLYTES IN DEXTROSE 25 W CALCIUM IN PLASTIC CONTAINER.
AMINOSYN 3.5% M IN PLASTIC CONTAINER vs AMINOSYN II 4.25% W/ ELECTROLYTES IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 3.5% M is a mixture of essential and non-essential amino acids used for parenteral nutrition. It provides substrates for protein synthesis, thereby maintaining nitrogen balance and supporting tissue repair and growth.
Amino acids serve as substrates for protein synthesis and nitrogen balance; dextrose provides caloric energy for metabolic processes; electrolytes maintain fluid and electrolyte homeostasis.
Intravenous infusion: 500 mL to 1 L of 3.5% amino acid solution per day for adults; rate not to exceed 0.1 g amino acids/kg/hr.
Intravenous infusion: 500 mL to 2 L per day, administered via central line at a rate not exceeding 1 mL/min for initial 30 minutes, then increase to 2 mL/min if tolerated. Dose based on patient's protein and energy requirements; typical protein equivalent: 4.25 g/100 mL.
None Documented
None Documented
Variable (minutes to hours) due to rapid metabolic utilization; terminal half-life in plasma is <10 minutes for most amino acids.
Amino acids: variable, ~10-30 min for most; dextrose: ~1-2 h terminal half-life in healthy adults, prolonged in renal impairment.
Renal: >90% as amino acids and metabolites; negligible biliary/fecal elimination.
Renal excretion of amino acids and dextrose metabolites; >90% of infused amino nitrogen is excreted renally as urea, with minimal biliary/fecal elimination.
Category C
Category C
Amino Acid Solution
Amino Acid Solution